Cellebrite DI Q4 2023 Adj EPS $0.11 Beats $0.06 Estimate, Sales $93.01M Beat $85.54M Estimate
Portfolio Pulse from Benzinga Newsdesk
Cellebrite DI (NASDAQ:CLBT) reported Q4 2023 adjusted EPS of $0.11, surpassing the $0.06 estimate, and sales of $93.01M, exceeding the $85.54M estimate. This represents a 37.5% increase in EPS and a 25.66% increase in sales from the same period last year.
February 15, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cellebrite DI reported a significant beat on both EPS and sales estimates for Q4 2023, with EPS at $0.11 vs. $0.06 estimate and sales at $93.01M vs. $85.54M estimate.
Cellebrite DI's earnings and sales beat are significant indicators of the company's strong performance and growth, likely leading to positive investor sentiment and a potential increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100